PLOD1 (fragile foal syndrome)

Crossing two of them

Born, and then lost

Lethal at birth, so the foal really is born: it gets a name, a record and a place in the family tree, and then dies over a few seconds with a chat line naming what took it.

That is deliberate. A pairing that silently produced nothing would teach a player nothing about the two horses they just bred, and the whole value of a recessive lethal is that it tells you something about both parents at once. The mechanics of the death are on the trait system page.

The highest carrier rate of the four foal lethals, because in the real population it is the one hiding inside the largest number of otherwise excellent animals.

Its gene carrot

Gene key

horsegenetics.plod1

Priority

88

Alleles

ffs N

Outcomes

wild, plod1-carrier, fragile-foal-syndrome

Coat effect

none — every outcome is a wild type

Default allele

N

Wild population

2.6% of founders carry one copy; none carries two

Founder draws

1 × nextFloat()

Catalogue entries

1 — it never changes what a horse looks like

The combination table

At a glance

The genomic notation reads C>T while the transcript reads G>A. That is not an inconsistency: PLOD1 is transcribed from the opposite DNA strand, so the same physical event is written differently depending on which reference you are counting from. OMIA 001982

What breaks

PLOD1 encodes lysyl hydroxylase 1, active during collagen production. Collagen is the tensile-strength protein of skin, tendon, ligament, fascia, blood-vessel wall and joint capsule. Before collagen becomes a working fibre, selected lysine residues in the collagen chains have to be hydroxylated; those modified residues then provide the sites for glycosylation and, above all, for the orderly intermolecular cross-links that hold the fibril together.

Lose that step and the chain runs: poor lysine hydroxylation → abnormal cross-linking → mechanically weak connective tissue. It is the same biology as kyphoscoliotic Ehlers-Danlos syndrome from PLOD1 deficiency in people — faulty collagen maturation, and tissue that cannot take ordinary mechanical stress. PMC8524838

The substitution is glycine to arginine at residue 678. Glycine is very small and flexible; arginine is large and positively charged. In an enzyme whose three-dimensional shape is what lets it recognise a collagen substrate, that is a substitution with an obvious way to do damage.

The case for c.2032G>A being causal: affected foals tested so far have been homozygous, parents fit the carrier pattern, the clinical signs match loss of a collagen-processing enzyme, the phenotype parallels the human PLOD1 disease, and heterozygotes in reported studies were clinically normal. One nuance worth carrying: the variant was first described in a patent application rather than a peer-reviewed molecular-discovery paper, with later clinical, population and genetic work reinforcing the association. Residual enzyme activity in affected equine tissue has never been comprehensively quantified the way it has for some human PLOD1 disorders.

What an affected foal looks like

The hallmark is profound skin fragility — skin so thin and hyperextensible that it tears under ordinary handling, ordinary movement, or the mechanical forces of birth itself. Reported findings include large open lesions on the limbs, neck, abdomen, perineum or tail region; loose, easily torn skin; areas of missing skin or skin separation; large wounds from minimal trauma; and exposed underlying tissue in severe cases.

That is not a dermatological defect. Skin is simply the most visible surface of a body-wide connective-tissue disorder. Affected foals may also have lax and hyperextensible joints, limb deformity or instability, flexural deformity, and in some cases abnormal spinal-canal or vertebral development. Severe cases reach the internal tissues: abdominal-wall defects, small-intestinal eventration, aortic perforating lesions.

Because the foals are generally non-viable, there is no evidence about adult conformation, soundness or athletic development in a ffs/ffs horse. The genotype’s phenotype is neonatal failure, not a recognisable adult “fragile build”.

The carrier question, which is where the misinformation lives

What is supported. Heterozygotes are generally described as clinically unaffected. No published study has confirmed a carrier syndrome of fragile skin, joint laxity, tendon weakness, poor growth, reduced soundness or impaired performance.

The most useful evidence on athletic risk is a 716-horse Thoroughbred case-control study. It found 17 carriers — 2.4% — and no homozygotes, and carrier and allele frequencies did not differ significantly between horses with catastrophic musculoskeletal breakdown and multiple control groups, including older racehorses and racehorses from the same track and season. The conclusion was that this variant is not a genetic risk factor for catastrophic breakdown in Thoroughbreds. PMC7062577

That is not a proof that no carrier ever tears a tendon — those are common multifactorial problems. It is that the published evidence does not support treating carrier status as a demonstrated cause of unsoundness.

What is possible but unproven. Breeders have wondered whether one copy subtly changes collagen quality, either downward (injury susceptibility) or upward (more elasticity, better movement, a particular sport-horse type). Both are speculative. The Irish population study notes that such theories exist and that no study has confirmed a collagen-defective condition in heterozygotes. It also notes reported statistical correlations between the variant and estimated breeding values for gaits and rideability in one Warmblood analysis — which is not proof of anything, since correlations like that arise readily from breed-family structure, influential sires, selection history, linked genes, management and uneven sampling.

Inheritance

Not sex-linked; colts and fillies carry and are affected equally. The 25% is per pregnancy, not a promise about four of them. The preventive step is one line long: do not mate two carriers. A carrier bred to a tested-clear mate cannot produce an affected foal and keeps whatever else it was worth keeping for.

Breeds and frequency

Strongest in Warmblood and Warmblood-derived sport horses, present at low frequency in Thoroughbreds, and variably detected or absent in limited samples of other breeds. A 2020 survey genotyped 4,081 horses across Europe and the US and found 200 carriers across 21 breeds — an overall 4.9%, concentrated in the Warmblood types. Genes 11(12):1518

Across Warmbloods generally, UC Davis-associated work estimates roughly 9–11% carriers, varying sharply by studbook, country and line. UC Davis CEH

The 2020 survey found no carriers in its samples of Arabian, Akhal-Teke, Appaloosa, Friesian, Friesian cross, Hucul, Lipizzan, Norwegian Fjord, Polish Heavy Draft, Polish Konik, Quarter Horse, Rocky Mountain Horse, Shetland Pony, Shire and Tennessee Walker, among others — including 302 Arabians and 112 Quarter Horses. “Not detected in this sample” is not “impossible in the breed”: the same survey found none among 146 European Thoroughbreds while the larger US study found 17 among 716.

Where the allele came from — unsolved

Several proposed founders have been tested and did not hold up. The influential English Thoroughbred stallion Dark Ronald (1905–1928) was suggested from pedigree patterns, but testing of preserved skin exhibits found him homozygous normal at the variant site. The Arabian stallion Bairactar Or. Ar. (1813–1838) was also proposed, and historical DNA testing did not support him either. Pedigree analysis of known carriers identified a Hanoverian stallion born in 1861 as the most recent common ancestor of one carrier group — a point of convergence in those pedigrees, not necessarily where the mutation arose.

The current reading is that WFFS was enriched by historical Warmblood breeding and a few influential lines, possibly with older Thoroughbred contribution, and that the horse in which c.2032G>A first appeared remains unknown.

What is settled, and what is not

Well established. PLOD1 encodes an enzyme essential for collagen cross-linking; c.2032G>A p.Gly678Arg causes WFFS; the locus is on ECA3; inheritance is autosomal recessive; homozygotes have a severe congenital systemic connective-tissue disorder with thin fragile hyperextensible skin, wounds and skin loss, joint and limb abnormalities and sometimes abdominal, intestinal, vascular or spinal involvement; affected foals are usually stillborn, non-viable or euthanised; carriers are clinically normal in the literature; the allele is concentrated in Warmbloods and present at low frequency in Thoroughbreds.

Plausible but unsettled. Whether some affected pregnancies are lost earlier in gestation; the full biochemical signature of the collagen defect in affected horses; whether all affected foals show obvious skin lesions at birth (they do not); the founder and date of origin; and the true carrier frequency inside every national population, family and registry.

Not supported. That carrier status causes catastrophic breakdown in Thoroughbreds; that carriers have a predictable weak-skin, weak-tendon, loose-joint or fragile-bone syndrome; that carriers are inherently faster, better jumpers, more elastic movers or more rideable; that the variant predicts coat colour, white markings or eye colour; or that carriers should automatically be removed from breeding merely for carrying it.